Joyce Oleszek
Concepts (84)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Off-Label Use | 1 | 2020 | 49 | 0.610 |
Why?
| | Botulinum Toxins | 1 | 2020 | 46 | 0.590 |
Why?
| | Neuromuscular Agents | 1 | 2020 | 45 | 0.580 |
Why?
| | Cerebral Palsy | 3 | 2025 | 132 | 0.530 |
Why?
| | Neuromuscular Diseases | 1 | 2020 | 146 | 0.530 |
Why?
| | Muscle Spasticity | 3 | 2025 | 63 | 0.400 |
Why?
| | Muscular Dystrophy, Duchenne | 3 | 2020 | 91 | 0.340 |
Why?
| | Rhizotomy | 2 | 2025 | 5 | 0.270 |
Why?
| | Spinal Nerve Roots | 2 | 2025 | 29 | 0.270 |
Why?
| | Torticollis | 1 | 2005 | 17 | 0.230 |
Why?
| | Muscle Hypertonia | 1 | 2025 | 8 | 0.230 |
Why?
| | Muscle Relaxants, Central | 1 | 2025 | 14 | 0.230 |
Why?
| | Muscle Hypotonia | 1 | 2025 | 33 | 0.220 |
Why?
| | Infusion Pumps, Implantable | 1 | 2025 | 26 | 0.220 |
Why?
| | Baclofen | 1 | 2025 | 21 | 0.220 |
Why?
| | Botulinum Toxins, Type A | 1 | 2005 | 58 | 0.210 |
Why?
| | Electromyography | 2 | 2025 | 415 | 0.210 |
Why?
| | Hip Dislocation | 1 | 2024 | 53 | 0.210 |
Why?
| | Injections, Intramuscular | 2 | 2020 | 141 | 0.200 |
Why?
| | Low Back Pain | 1 | 2025 | 106 | 0.200 |
Why?
| | Social Stigma | 1 | 2025 | 171 | 0.190 |
Why?
| | Joint Instability | 1 | 2024 | 182 | 0.180 |
Why?
| | Urinary Incontinence | 1 | 2022 | 64 | 0.180 |
Why?
| | Chronic Pain | 1 | 2025 | 290 | 0.160 |
Why?
| | Child, Preschool | 10 | 2025 | 11787 | 0.140 |
Why?
| | Anxiety | 1 | 2025 | 1109 | 0.130 |
Why?
| | Cranial Nerve Diseases | 1 | 2017 | 43 | 0.130 |
Why?
| | Movement Disorders | 1 | 2017 | 69 | 0.120 |
Why?
| | Muscular Diseases | 1 | 2017 | 108 | 0.120 |
Why?
| | Child | 10 | 2025 | 22633 | 0.120 |
Why?
| | Ventricular Dysfunction, Left | 1 | 2020 | 392 | 0.120 |
Why?
| | Myelitis | 1 | 2017 | 107 | 0.120 |
Why?
| | Self-Help Devices | 1 | 2015 | 24 | 0.110 |
Why?
| | Problem Behavior | 1 | 2015 | 102 | 0.100 |
Why?
| | Growth | 1 | 2013 | 49 | 0.100 |
Why?
| | Infant | 6 | 2025 | 10034 | 0.090 |
Why?
| | Adrenal Cortex Hormones | 1 | 2015 | 478 | 0.090 |
Why?
| | Attention Deficit Disorder with Hyperactivity | 1 | 2015 | 428 | 0.080 |
Why?
| | Male | 11 | 2025 | 72315 | 0.070 |
Why?
| | Adolescent | 6 | 2025 | 22428 | 0.070 |
Why?
| | Muscle, Skeletal | 1 | 2017 | 1795 | 0.060 |
Why?
| | Spinal Cord Neoplasms | 1 | 2007 | 41 | 0.060 |
Why?
| | Humans | 12 | 2025 | 144759 | 0.060 |
Why?
| | Registries | 1 | 2015 | 2385 | 0.060 |
Why?
| | Retrospective Studies | 5 | 2025 | 17066 | 0.060 |
Why?
| | Depression | 1 | 2015 | 1558 | 0.060 |
Why?
| | Treatment Outcome | 3 | 2025 | 11679 | 0.060 |
Why?
| | Injections, Spinal | 1 | 2025 | 120 | 0.060 |
Why?
| | Young Adult | 4 | 2025 | 14105 | 0.050 |
Why?
| | Muscular Atrophy, Spinal | 1 | 2024 | 25 | 0.050 |
Why?
| | Female | 8 | 2025 | 78271 | 0.050 |
Why?
| | Drug Administration Schedule | 1 | 2005 | 779 | 0.050 |
Why?
| | Acetabulum | 1 | 2024 | 111 | 0.050 |
Why?
| | Follow-Up Studies | 2 | 2017 | 5408 | 0.050 |
Why?
| | Recovery of Function | 1 | 2005 | 707 | 0.040 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2005 | 2027 | 0.040 |
Why?
| | Spinal Cord | 1 | 2022 | 380 | 0.040 |
Why?
| | Pediatrics | 1 | 2007 | 1114 | 0.030 |
Why?
| | Adult | 4 | 2025 | 40449 | 0.030 |
Why?
| | Severity of Illness Index | 1 | 2005 | 2925 | 0.030 |
Why?
| | Neural Conduction | 1 | 2017 | 92 | 0.030 |
Why?
| | Atrophy | 1 | 2017 | 201 | 0.030 |
Why?
| | Echocardiography | 1 | 2020 | 652 | 0.030 |
Why?
| | Disease Progression | 1 | 2024 | 2847 | 0.030 |
Why?
| | Stroke Volume | 1 | 2020 | 651 | 0.030 |
Why?
| | Risk Assessment | 1 | 2005 | 3671 | 0.030 |
Why?
| | Glucocorticoids | 1 | 2020 | 535 | 0.030 |
Why?
| | Cross-Sectional Studies | 1 | 2025 | 5868 | 0.020 |
Why?
| | Patient Reported Outcome Measures | 1 | 2017 | 488 | 0.020 |
Why?
| | Body Height | 1 | 2013 | 202 | 0.020 |
Why?
| | Body Weight | 1 | 2013 | 976 | 0.020 |
Why?
| | Cohort Studies | 1 | 2020 | 5960 | 0.020 |
Why?
| | Infant, Newborn | 1 | 2020 | 6429 | 0.020 |
Why?
| | Colorado | 1 | 2017 | 4564 | 0.020 |
Why?
| | Neurilemmoma | 1 | 2007 | 25 | 0.020 |
Why?
| | Astrocytoma | 1 | 2007 | 129 | 0.010 |
Why?
| | Meningioma | 1 | 2007 | 87 | 0.010 |
Why?
| | Neuroblastoma | 1 | 2007 | 174 | 0.010 |
Why?
| | Body Mass Index | 1 | 2013 | 2438 | 0.010 |
Why?
| | Magnetic Resonance Imaging | 1 | 2017 | 3863 | 0.010 |
Why?
| | Middle Aged | 1 | 2025 | 35875 | 0.010 |
Why?
| | Sex Factors | 1 | 2007 | 2112 | 0.010 |
Why?
| | United States | 1 | 2015 | 15966 | 0.010 |
Why?
| | Risk Factors | 1 | 2007 | 10779 | 0.010 |
Why?
|
|
Oleszek's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|